Related Experiment Videos
Amiodarone for long-term management of patients with hypertrophic cardiomyopathy
Insights
Amiodarone effectively suppressed arrhythmias and prevented sudden death in hypertrophic cardiomyopathy patients. Long-term use demonstrated efficacy with manageable side effects, improving quality of life.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) presents significant risks including serious arrhythmias and sudden cardiac death.
- Effective long-term management strategies for symptomatic HCM patients are crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of long-term amiodarone treatment in patients with hypertrophic cardiomyopathy and serious arrhythmias or refractory chest pain.
Main Methods:
- Fifty-three HCM patients received amiodarone (6-96 months) after loading.
- Dosing was adjusted based on ECG, plasma levels, and side-effect monitoring.
- Follow-up included arrhythmia assessment, symptom evaluation, and adverse event reporting.
Main Results:
- Amiodarone suppressed ventricular tachycardia in 92% of patients (100-400 mg/day), with no sudden deaths.
- Supraventricular tachycardia and atrial fibrillation episodes were abolished in most patients.
- Chest pain remained stable or improved in the majority despite beta-blocker withdrawal.
- Discontinuation due to side effects occurred in 3 patients, with successful re-initiation at lower doses in two.
Conclusions:
- Long-term amiodarone therapy is effective in suppressing serious arrhythmias and preventing sudden death in HCM patients.
- The drug demonstrates a favorable safety profile with manageable side effects for long-term use.
- Amiodarone can improve symptoms and quality of life in HCM patients with refractory arrhythmias.
Abstract:
Fifty-three patients with hypertrophic cardiomyopathy who had serious arrhythmias (45 patients), refractory chest pain (5 patients) or a high risk of sudden death (3 patients) received amiodarone for 6 to 96 months (median 18) after completion of a loading and an initial maintenance period. The dose of amiodarone was altered by 50 to 200 mg/day at 3- to 6-month intervals, guided by electrocardiographic monitoring, plasma drug level measurements and side-effect questionnaires. Ventricular tachycardia was suppressed in 24 patients (92%) with doses of 100 to 400 mg/day (median 300); none died suddenly during a mean follow-up of 27 months. Although symptomatic episodes of frequent or prolonged supraventricular tachycardia or paroxysmal atrial fibrillation/flutter were abolished in 8 of 9 patients on 100 to 600 mg/day (median 300), in 1 patient incessant atrial flutter developed that was relatively refractory to direct-current cardioversion. In 11 patients with atrial fibrillation, sinus rhythm was restored in 7 (after direct-current cardioversion in 3) with doses of 100 to 600 mg/day (median 300) and has been maintained in 5 with associated improvement in symptoms. Despite discontinuation of beta-blocker therapy, chest pain was unchanged in 17 patients, was impaired in 11 and was worse in only 2. Amiodarone was discontinued in 3 patients; in 1 because of hair loss, in 1 because of neurologic symptoms and in 1 because of facial discoloration; in the latter 2 patients, amiodarone was restarted after 1 and 14 months, and was tolerated and effective at the lower dosage.(ABSTRACT TRUNCATED AT 250 WORDS)